<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01640730</url>
  </required_header>
  <id_info>
    <org_study_id>KLT-NSCLC-004</org_study_id>
    <nct_id>NCT01640730</nct_id>
  </id_info>
  <brief_title>Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer</brief_title>
  <official_title>An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>KangLaiTe USA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>KangLaiTe USA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is for patients with advanced non small cell lung cancer that has progressed
      despite standard of care. The purpose of the study is to see if Kanglaite injection has any
      effect on survival.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    poor enrollment
  </why_stopped>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>from date of enrollment until date of death from any cause assessed up to 12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioimpedance Phase Angle</measure>
    <time_frame>measured each month up to one year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Palliation Response Measure</measure>
    <time_frame>each month up to one year</time_frame>
    <description>quality of life survey and performance status</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Stage IV NSCLC</condition>
  <arm_group>
    <arm_group_label>Kanglaite injection</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kanglaite Injection</intervention_name>
    <description>30gm IV infusion 5 days a week for 3 weeks every 28 days</description>
    <arm_group_label>Kanglaite injection</arm_group_label>
    <other_name>KLTi</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  confirmed (within last 3 months)progressive Stage IV NSCLC

          -  estimated life span of 3 months

          -  phase angle of at least 5 as measured by bioimpedance

        Exclusion Criteria:

          -  currently taking a lipid lowering medications

          -  has an imminently life threatening condition

          -  has pre-existing liver disease

          -  known allergy to soybeans

          -  uncontrolled diabetes or uncontrolled disturbance of lipid metabolism

          -  pregnant or lactating

          -  has a pacemaker or other implantable electronic medical device
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The West Clinic</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 15, 2012</study_first_submitted>
  <study_first_submitted_qc>July 11, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 16, 2012</study_first_posted>
  <last_update_submitted>January 15, 2014</last_update_submitted>
  <last_update_submitted_qc>January 15, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 16, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

